Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Here’s What Happened

Nyxoah SA (NASDAQ:NYXH)’s share price fell 2.9% on Friday . The stock traded as low as $4.69 and last traded at $4.73. 24,570 shares traded hands during trading, a decline of 52% from the average session volume of 51,594 shares. The stock had previously closed at $4.87.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and issued a $9.00 target price (down from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nyxoah in a research note on Monday, December 1st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nyxoah has a consensus rating of “Moderate Buy” and an average price target of $12.67.

Nyxoah Stock Down 2.9%

The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.41 and a current ratio of 1.70. The stock’s 50 day moving average price is $5.26 and its 200-day moving average price is $6.27. The company has a market cap of $161.10 million, a PE ratio of -1.90 and a beta of 1.55.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Friday, November 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13). Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%.The business had revenue of $2.31 million during the quarter, compared to analysts’ expectations of $1.95 million. On average, analysts predict that Nyxoah SA will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On Nyxoah

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the period. Raymond James Financial Inc. bought a new position in shares of Nyxoah in the second quarter worth approximately $70,000. Citadel Advisors LLC purchased a new position in shares of Nyxoah in the third quarter worth $98,000. Shay Capital LLC purchased a new position in shares of Nyxoah in the second quarter worth $374,000. Finally, Kovack Advisors Inc. raised its holdings in Nyxoah by 148.2% during the 2nd quarter. Kovack Advisors Inc. now owns 57,827 shares of the company’s stock valued at $433,000 after buying an additional 34,532 shares during the last quarter.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.